​

iTeos Therapeutics (ITOS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ITOS Stock Forecast

iTeos Therapeutics (ITOS) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $11.25, with a high of $12.00 and a low of $9.00. This represents a 12.73% increase from the last price of $9.98.

$7 $9 $11 $13 $15 $17 $18 High: $12 Avg: $11.25 Low: $9 Last Closed Price: $9.98

ITOS Stock Rating

iTeos Therapeutics stock's rating consensus is Hold, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (42.86%), 4 Hold (57.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 7 0 4 3 Strong Sell Sell Hold Buy Strong Buy

ITOS Price Target Upside V Benchmarks

TypeNameUpside
StockiTeos Therapeutics12.73%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts558
Avg Price Target$11.60$11.60$17.75
Last Closing Price$9.98$9.98$9.98
Upside/Downside16.23%16.23%77.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 251-5--6
May, 2533---6
Apr, 2533---6
Mar, 2533---6
Feb, 2533---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 28, 2025Eva Fortea VerdejoWells Fargo$12.00$10.0619.28%20.24%
May 28, 2025David NierengartenWedbush$12.00$10.0619.28%20.24%
May 14, 2025Eva Fortea VerdejoWells Fargo$13.00$6.9287.86%30.26%
May 14, 2025Christopher RaymondRaymond James$12.00$6.9273.41%20.24%
May 14, 2025Daina GrayboschLeerink Partners$9.00$6.9230.06%-9.82%
Mar 06, 2025Wells Fargo$17.00$7.10139.44%70.34%
Sep 16, 2024Christopher RaymondRaymond James$36.00$16.70115.57%260.72%
Aug 13, 2024Eva Fortea VerdejoWells Fargo$31.00$14.50113.79%210.62%
May 13, 2024Swayampakula RamakanthH.C. Wainwright$46.00$17.44163.76%360.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 28, 2025WedbushNeutraldowngrade
May 14, 2025Wells FargoOverweightOverweighthold
May 14, 2025Piper SandlerOverweightOverweighthold
May 14, 2025H.C. WainwrightBuyNeutraldowngrade
Sep 16, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Aug 13, 2024Wells FargoOverweightinitialise
May 13, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.10$2.72$-3.15$-3.32----
Avg Forecast$2.09$2.71$-3.40$-3.19$-3.80$-3.96$-3.30$-2.28
High Forecast$3.34$2.71$-2.37$-3.07$-2.81$-2.24$-2.25$-2.28
Low Forecast$1.84$2.71$-4.14$-3.41$-5.23$-5.44$-5.11$-2.28
Surprise %191.87%0.37%-7.35%4.08%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$344.77M$267.63M$12.60M$35.00M----
Avg Forecast$189.74M$254.88M$20.08M$35.00M$7.48M$15.68M$41.32M$89.85M
High Forecast$276.66M$254.88M$50.00M$35.00M$7.48M$15.68M$41.32M$89.85M
Low Forecast$172.36M$254.88M$12.60M$35.00M$7.48M$15.68M$41.32M$89.85M
Surprise %81.71%5.00%-37.27%-----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$214.52M$96.65M$-112.64M$-134.41M----
Avg Forecast$74.80M$97.01M$-112.64M$-121.25M$-178.32M$-137.30M$-131.64M$-81.54M
High Forecast$119.36M$97.01M$-84.87M$-109.65M$-100.32M$-80.05M$-80.56M$-81.54M
Low Forecast$65.90M$97.01M$-147.89M$-122.08M$-187.18M$-194.55M$-182.72M$-81.54M
Surprise %186.78%-0.37%-10.85%----

ITOS Forecast FAQ

Is iTeos Therapeutics stock a buy?

iTeos Therapeutics stock has a consensus rating of Hold, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that iTeos Therapeutics is a neutral investment for most analysts.

What is iTeos Therapeutics's price target?

iTeos Therapeutics's price target, set by 7 Wall Street analysts, averages $11.25 over the next 12 months. The price target range spans from $9 at the low end to $12 at the high end, suggesting a potential 12.73% change from the previous closing price of $9.98.

How does iTeos Therapeutics stock forecast compare to its benchmarks?

iTeos Therapeutics's stock forecast shows a 12.73% upside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for iTeos Therapeutics over the past three months?

  • June 2025: 16.67% Strong Buy, 0% Buy, 83.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is iTeos Therapeutics’s EPS forecast?

iTeos Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.8, marking a 14.46% increase from the reported $-3.32 in 2024. Estimates for the following years are $-3.96 in 2026, $-3.3 in 2027, and $-2.28 in 2028.

What is iTeos Therapeutics’s revenue forecast?

iTeos Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $7.48M, reflecting a -78.63% decrease from the reported $35M in 2024. The forecast for 2026 is $15.68M, followed by $41.32M for 2027, and $89.85M for 2028.

What is iTeos Therapeutics’s net income forecast?

iTeos Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-178M, representing an 32.67% increase from the reported $-134M in 2024. Projections indicate $-137M in 2026, $-132M in 2027, and $-81.541M in 2028.